Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7096292 | 0.88 | GRIN2B (0.52) | GRIN2BCYP2D6CYP2C9CYP3A4EGLN1 | |
| SCHEMBL5409925 | 0.87 | GRIN2B (0.55) | GRIN2BCYP2D6CYP2C9CYP3A4FAAH | |
| SCHEMBL20775269 | 0.85 | GRIN2B (0.66) | GRIN2BCYP2D6CYP2C9CYP3A4CARM1 | |
| SCHEMBL5399959 | 0.85 | GRIN2B (0.53) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL6355548 | 0.85 | CYP2D6 (0.48) | GRIN2BCYP2D6CYP2C9EGLN1CARM1 | |
| SCHEMBL6369662 | 0.81 | ALDH1A1 (0.49) | GRIN2BEGLN1BRD4KDM4EALDH1A1 | |
| SCHEMBL3650096 | 0.81 | GRIN2B (0.56) | GRIN2BCYP2D6CYP2C9CYP3A4CARM1 | |
| SCHEMBL6344009 | 0.80 | SCD (0.60) | GRIN2BCYP2D6CYP2C9EGLN1KDM4E | |
| SCHEMBL5348026 | 0.80 | GRIN2B (1.00) | GRIN2BCYP2D6CYP2C9CYP3A4 | |
| SCHEMBL4577310 | 0.79 | FAAH (0.68) | GRIN2BALDH1A1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289953-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6784182-B2 | AND FACTOR XA INHIBITORS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | ELI LILLY AND COMPANY | 2004-08-31 | — | — | US | disclosed |
| EP-1289953-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| US-20020151724-A1 | Serine protease inhibitors | ELI LILLY AND COMPANY | 2002-10-17 | — | — | US | disclosed |
| WO-2001096304-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151724-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | GRIN2B 4499/4885CYP2D6 2052/4885CYP2C9 2235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.